Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

4.050 -0.450 (-10.00%)
Streaming Delayed Price Updated: 12:06 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers 
Via Benzinga
Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate
Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN). 
Via Benzinga
After-Hours Action: Why Kezar Life Sciences Stock Is Soaring
Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib. 
Via Benzinga
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
Billionaire Israel Englander Is Betting Big on These 5 Stocks
Millennium Management's Israel Englander is in focus after the billionaire's fund purchased several stocks this month. 
Via InvestorPlace
Wells Fargo Analyst Has Questions On Kezar's Lupus Nephritis Data Readout, Stock Plunges
Via Benzinga
Kezar Life's Lead Asset Fails To Top Placebo In Muscle Inflammation Disease
Via Benzinga
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for... 
Via Benzinga
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Mid-Afternoon Market Update: Crude Oil Jumps 5%; Fed Boosts Interest Rates By 0.5%
U.S. stocks traded mixed toward the end of trading, after the Federal Reserve announced its policy decision. 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after... 
Via Benzinga
Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. 
Via Benzinga
Why Kezar Life Sciences Shares Are Getting Hammered
Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading lower by 38.23% at $7.61 after the company announced top-line results from its PRESIDIO Phase 2 clinical trial of... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points
U.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday. 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Insider Weekends: Return Of The Meme Stocks - GameStop (GME) And AMC Entertainment (AMC)
  
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Allego N.V. (NYSE: ALLG) shares surged 114.1% to close at $17.73 on Wednesday after the company announced the completion of its merger agreement with Spartan Acquisition... 
Via Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allego N.V. (NYSE: ALLG) shares jumped 158.5% to $21.41 after the company announced the completion of its merger agreement with Spartan Acquisition Corp., which resulted... 
Via Benzinga
Here's Why Kezar Life Sciences Shares Are Moving
Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading higher by 5.0% at $16.08 after HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target... 
Via Benzinga
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Appoints Courtney Wallace to its Board of Directors
From Kezar Life Sciences
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS